Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis

被引:118
作者
Arpin, D
Perol, D
Blay, JY
Falchero, L
Claude, L
Vuillermoz-Blas, S
Martel-Lafay, I
Ginestet, C
Alberti, L
Nosov, D
Etienne-Mastroianni, B
Cottin, V
Perol, M
Guerin, JC
Cordier, JF
Carrie, C
机构
[1] Hop Croix Rousse, Dept Pneumol, F-69317 Lyon, France
[2] Ctr Leon Berard, Dept Publ Hlth, Biostat Unit, F-69373 Lyon, France
[3] Ctr Leon Berard, INSERM, Radiat Oncol & Cytokines & Canc Res Unit, U590, F-69373 Lyon, France
[4] Hop St Joseph, Dept Pneumol, Lyon, France
[5] Hop Louis Pradel, Dept Pneumol, Lyon, France
[6] Hop Villefranche Sur Saone, Dept Pneumol, Villefranche, France
[7] Blokhin Canc Res Ctr, Moscow, Russia
关键词
D O I
10.1200/JCO.2005.01.7145
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To investigate variations of circulating serum levels of interleukin (IL-6), tumor necrosis factor alpha (TNF alpha), and interleukin-10 (IL-10) during three-dimensional conformal radiation therapy (3D-CRT) in patients with non-small-cell lung cancer and correlate these variations with the occurrence of radiation pneumonitis. Patients and Methods Ninety-six patients receiving 3D-CRT for stage I to III disease were evaluated prospectively. Circulating cytokine levels were determined before, every 2 weeks during, and at the end of treatment. Radiation pneumonitis was evaluated prospectively between 6 and 8 weeks after 3D-CRT. The predictive value of clinical, dosimetric, and biologic (cytokine levels) factors was evaluated both in univariate and multivariate analyses. Results Forty patients (44%) experienced score 1 or more radiation pneumonitis. No association was found between baseline cytokine levels and the risk of radiation pneumonitis. In the whole population, mean levels of TNFa, IL-6, and IL-10 remained stable during radiotherapy. IL-6 levels were significantly higher (P.047) during 3D-CRT in patients with radiation pneumonitis. In the multivariate analysis, covariations of IL-6 and IL-10 levels during the first 2 weeks of 3D-CRT were evidenced as independently predictive of radiation pneumonitis in this series (P = .011). Conclusion Early variations of circulating IL-6 and IL-10 levels during 3D-CRT are significantly associated with the risk of radiation pneumonitis. Variations of circulating IL-6 and IL-10 levels during 3D-CRT may serve as independent predictive factors for this complication.
引用
收藏
页码:8748 / 8756
页数:9
相关论文
共 42 条
[1]   Lung toxicity following chest irradiation in patients with lung cancer [J].
Abratt, RP ;
Morgan, GW .
LUNG CANCER, 2002, 35 (02) :103-109
[2]  
[Anonymous], 1995, RADIOTHER ONCOL, V35, P17
[3]   Plasma transforming growth factor β1 as a predictor of radiation pneumonitis [J].
Anscher, MS ;
Kong, FM ;
Andrews, K ;
Clough, R ;
Marks, LB ;
Bentel, G ;
Jirtle, RL .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 41 (05) :1029-1035
[4]   Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis [J].
Anscher, MS ;
Kong, FM ;
Marks, LB ;
Bentel, GC ;
Jirtle, RL .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 37 (02) :253-258
[5]   Increased IL-6 and TGF-β1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy [J].
Barthelemy-Brichant, N ;
Bosquée, L ;
Cataldo, D ;
Corhay, JL ;
Gustin, M ;
Seidel, L ;
Thiry, A ;
Ghaye, B ;
Nizet, M ;
Albert, A ;
Deneufbourg, JM ;
Bartsch, P ;
Nusgens, B .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (03) :758-767
[6]  
CHEN Y, 2002, J RAD ONCOL BIOL PHY, V49, P641
[7]   Radiation pneumonitis and early circulatory cytokine markers [J].
Chen, YY ;
Williams, J ;
Ding, I ;
Hernady, E ;
Liu, WM ;
Smudzin, T ;
Finkelstein, JN ;
Rubin, P ;
Okunieff, P .
SEMINARS IN RADIATION ONCOLOGY, 2002, 12 (01) :26-33
[8]   A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer:: clinical and dosimetric factors analysis [J].
Claude, L ;
Pérol, D ;
Ginestet, C ;
Falchero, L ;
Arpin, D ;
Vincent, M ;
Martel, I ;
Hominal, S ;
Cordier, JF ;
Carrie, C .
RADIOTHERAPY AND ONCOLOGY, 2004, 71 (02) :175-181
[9]   IL-10, an inflammatory/inhibitory cytokine, but not always [J].
Conti, P ;
Kempuraj, D ;
Kandere, K ;
Di Gioacchino, M ;
Barbacane, RC ;
Castellani, ML ;
Felaco, M ;
Boucher, W ;
Letourneau, R ;
Theoharides, TC .
IMMUNOLOGY LETTERS, 2003, 86 (02) :123-129
[10]   A RANDOMIZED PHASE-I/II TRIAL OF HYPERFRACTIONATED RADIATION-THERAPY WITH TOTAL DOSES OF 60.0 GY TO 79.2 GY - POSSIBLE SURVIVAL BENEFIT WITH GREATER-THAN-OR-EQUAL-TO 69.6 GY IN FAVORABLE PATIENTS WITH RADIATION-THERAPY ONCOLOGY GROUP STAGE-III NON-SMALL-CELL LUNG-CARCINOMA - REPORT OF RADIATION-THERAPY ONCOLOGY GROUP 83-11 [J].
COX, JD ;
AZARNIA, N ;
BYHARDT, RW ;
SHIN, KH ;
EMAMI, B ;
PAJAK, TF .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (09) :1543-1555